Project Grant K08AI193352
Award Date 8/5/25
Completion Date 7/31/30
Dollars Obligated $162K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $460,625 Project Grant to The Feinstein Institutes For Medical Research in New York, USA. The grant, awarded on July 7, 2025 with an ultimate completion date of June 30, 2027, supports research to investigate the role of post-sepsis exercise therapy in regulating CD4 T cell immunity against secondary Pseudomonas aeruginosa...
- This $479,249 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to understand the molecular mechanisms regulating neutrophil proinflammatory and adhesive activities in sepsis. The project aims to investigate the role of neutrophil A20 signaling in contributing to organ damage in sepsis. Specifically, the research will: 1) Determine the molecular...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $418,750.00 to The Feinstein Institutes for Medical Research to conduct research on T cell receptor-mediated T cell activation in neonatal and pediatric sepsis. The goal is to gain insight into how T cell memory influences sepsis-associated organ dysfunction, by comparing responses between human neonates with sepsis and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $197,640 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), on July 16, 2025. This grant supports research to investigate the contribution of a novel monocyte transcriptional state, termed Monocyte Substate 1 (MS1), to sepsis immunopathogenesis and patient heterogeneity. The project will...
- This Project Grant award for $684,206, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a nanoparticle-based immunotherapy to address the complex immune dysregulation associated with sepsis. The funds will support research to advance the development of "immunomodulatory nanoparticles" (INPs) - a drug-free class of poly(lactic acid)-based nanoparticles designed to...
- The University of Rochester received a $462,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to study how the human microbiome regulates neutrophil responses in sepsis. The research aims to determine if differential priming of the immune system by healthy blood microbiomes predisposes patients to heterogeneous responses to sepsis. Preliminary evidence suggests that microbiome-mediated training of...
- The federal Project Grant award of $3,204,624.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA program, supports research to define the molecular and cellular mechanisms of non-canonical inflammasome responses to lipopolysaccharide (LPS) in mice and humans. The research aims to provide essential insight for developing improved therapeutics to reduce human sepsis, as well as immune adjuvants to enhance host...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $101,982 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Massachusetts Medical School (UMMS) to conduct research on the "Temporal Regulation of mRNA Biogenesis in Immune Responses." This 21-month project, running from May 2025 to February 2027, seeks to uncover mechanistic insights into the regulation and impact of stimulus-induced immune mRNA...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $831,755 over 5 years to New York University (NYU) to conduct research on the role of lung-resident macrophage subsets in regulating type 2 immune responses and trained immunity. The research aims to elucidate the distinct functions of different macrophage populations, particularly nerve- and...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research grant program (CFDA 93.855), has awarded a $194,740 Project Grant to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct research on establishing lung resident self-antigen-specific CD4+ regulatory T cells (Tregs) following acute tissue injury. The 5-year project, starting on Mar 1, 2025 and ending on Feb 28, 2030, aims to characterize...